Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib.

Osoegawa A, Gills JJ, Kawabata S, Dennis PA.

Oncotarget. 2017 Jul 28;8(50):87044-87053. doi: 10.18632/oncotarget.19667. eCollection 2017 Oct 20.

2.

Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.

Lastwika KJ, Wilson W 3rd, Li QK, Norris J, Xu H, Ghazarian SR, Kitagawa H, Kawabata S, Taube JM, Yao S, Liu LN, Gills JJ, Dennis PA.

Cancer Res. 2016 Jan 15;76(2):227-38. doi: 10.1158/0008-5472.CAN-14-3362. Epub 2015 Dec 4.

3.

A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors.

Blumenthal GM, Gills JJ, Ballas MS, Bernstein WB, Komiya T, Dechowdhury R, Morrow B, Root H, Chun G, Helsabeck C, Steinberg SM, LoPiccolo J, Kawabata S, Gardner ER, Figg WD, Dennis PA.

Oncotarget. 2014 Sep 30;5(18):8161-72.

4.

SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines.

Dogan I, Kawabata S, Bergbower E, Gills JJ, Ekmekci A, Wilson W 3rd, Rudin CM, Dennis PA.

Lung Cancer. 2014 Jul;85(1):1-6. doi: 10.1016/j.lungcan.2014.03.021. Epub 2014 Mar 29.

5.

Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer.

Kawabata S, Chiang CT, Tsurutani J, Shiga H, Arwood ML, Komiya T, Gills JJ, Memmott RM, Dennis PA.

Oncotarget. 2014 Feb 28;5(4):1062-70.

6.

Repositioning metformin for cancer prevention and treatment.

Quinn BJ, Kitagawa H, Memmott RM, Gills JJ, Dennis PA.

Trends Endocrinol Metab. 2013 Sep;24(9):469-80. doi: 10.1016/j.tem.2013.05.004. Epub 2013 Jun 15. Review.

PMID:
23773243
7.

Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling.

Quinn BJ, Dallos M, Kitagawa H, Kunnumakkara AB, Memmott RM, Hollander MC, Gills JJ, Dennis PA.

Cancer Prev Res (Phila). 2013 Aug;6(8):801-10. doi: 10.1158/1940-6207.CAPR-13-0058-T. Epub 2013 Jun 14.

8.

Lipid molecules induce p38α activation via a novel molecular switch.

Tzarum N, Eisenberg-Domovich Y, Gills JJ, Dennis PA, Livnah O.

J Mol Biol. 2012 Dec 14;424(5):339-53. doi: 10.1016/j.jmb.2012.10.007. Epub 2012 Oct 16.

PMID:
23079240
9.

Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells.

Kawabata S, Gills JJ, Mercado-Matos JR, Lopiccolo J, Wilson W 3rd, Hollander MC, Dennis PA.

Cell Death Dis. 2012 Jul 19;3:e353. doi: 10.1038/cddis.2012.87.

10.

Ceramide mediates nanovesicle shedding and cell death in response to phosphatidylinositol ether lipid analogs and perifosine.

Gills JJ, Zhang C, Abu-Asab MS, Castillo SS, Marceau C, LoPiccolo J, Kozikowski AP, Tsokos M, Goldkorn T, Dennis PA.

Cell Death Dis. 2012 Jul 5;3:e340. doi: 10.1038/cddis.2012.72.

11.

Loss of cytoplasmic CDK1 predicts poor survival in human lung cancer and confers chemotherapeutic resistance.

Zhang C, Elkahloun AG, Robertson M, Gills JJ, Tsurutani J, Shih JH, Fukuoka J, Hollander MC, Harris CC, Travis WD, Jen J, Dennis PA.

PLoS One. 2011;6(8):e23849. doi: 10.1371/journal.pone.0023849. Epub 2011 Aug 24.

12.

Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells.

Zhang C, Elkahloun AG, Liao H, Delaney S, Saber B, Morrow B, Prendergast GC, Hollander MC, Gills JJ, Dennis PA.

Mol Cancer Ther. 2011 Jul;10(7):1137-48. doi: 10.1158/1535-7163.MCT-10-1028. Epub 2011 May 6.

13.

The chemopreventive agent myoinositol inhibits Akt and extracellular signal-regulated kinase in bronchial lesions from heavy smokers.

Han W, Gills JJ, Memmott RM, Lam S, Dennis PA.

Cancer Prev Res (Phila). 2009 Apr;2(4):370-6. doi: 10.1158/1940-6207.CAPR-08-0209. Epub 2009 Mar 31.

14.

Perifosine: update on a novel Akt inhibitor.

Gills JJ, Dennis PA.

Curr Oncol Rep. 2009 Mar;11(2):102-10. Review.

PMID:
19216841
15.

Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells.

Memmott RM, Gills JJ, Hollingshead M, Powers MC, Chen Z, Kemp B, Kozikowski A, Dennis PA.

Cancer Res. 2008 Jan 15;68(2):580-8. doi: 10.1158/0008-5472.CAN-07-3091.

16.

Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy.

Gills JJ, Lopiccolo J, Dennis PA.

Autophagy. 2008 Jan;4(1):107-9. Epub 2007 Oct 31.

PMID:
18000394
17.

Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo.

Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, Borojerdi J, Warfel NA, Gardner ER, Danish M, Hollander MC, Kawabata S, Tsokos M, Figg WD, Steeg PS, Dennis PA.

Clin Cancer Res. 2007 Sep 1;13(17):5183-94.

18.

Targeting Akt in cancer therapy.

LoPiccolo J, Granville CA, Gills JJ, Dennis PA.

Anticancer Drugs. 2007 Sep;18(8):861-74. Review.

PMID:
17667591
19.

Phosphatidylinositol ether lipid analogues that inhibit AKT also independently activate the stress kinase, p38alpha, through MKK3/6-independent and -dependent mechanisms.

Gills JJ, Castillo SS, Zhang C, Petukhov PA, Memmott RM, Hollingshead M, Warfel N, Han J, Kozikowski AP, Dennis PA.

J Biol Chem. 2007 Sep 14;282(37):27020-9. Epub 2007 Jul 13.

20.

A comparative evaluation of the anticancer properties of European and American elderberry fruits.

Thole JM, Kraft TF, Sueiro LA, Kang YH, Gills JJ, Cuendet M, Pezzuto JM, Seigler DS, Lila MA.

J Med Food. 2006 Winter;9(4):498-504.

PMID:
17201636
21.

Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt.

Gills JJ, Holbeck S, Hollingshead M, Hewitt SM, Kozikowski AP, Dennis PA.

Mol Cancer Ther. 2006 Mar;5(3):713-22.

22.

Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway.

Granville CA, Memmott RM, Gills JJ, Dennis PA.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):679-89. Review.

24.

Effect of deguelin on UVB-induced skin carcinogenesis.

Gills JJ, Kosmeder J 2nd, Moon RC, Lantvit DD, Pezzuto JM.

J Chemother. 2005 Jun;17(3):297-301.

PMID:
16041863
25.

Sulforaphane prevents mouse skin tumorigenesis during the stage of promotion.

Gills JJ, Jeffery EH, Matusheski NV, Moon RC, Lantvit DD, Pezzuto JM.

Cancer Lett. 2006 May 8;236(1):72-9. Epub 2005 Jul 1. Review.

PMID:
15993536
26.

Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells.

Tsurutani J, Castillo SS, Brognard J, Granville CA, Zhang C, Gills JJ, Sayyah J, Dennis PA.

Carcinogenesis. 2005 Jul;26(7):1182-95. Epub 2005 Mar 24.

PMID:
15790591
27.

Natural inhibitors of carcinogenesis.

Kinghorn AD, Su BN, Jang DS, Chang LC, Lee D, Gu JQ, Carcache-Blanco EJ, Pawlus AD, Lee SK, Park EJ, Cuendet M, Gills JJ, Bhat K, Park HS, Mata-Greenwood E, Song LL, Jang M, Pezzuto JM.

Planta Med. 2004 Aug;70(8):691-705. Review.

PMID:
15326546
28.

The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt.

Gills JJ, Dennis PA.

Expert Opin Investig Drugs. 2004 Jul;13(7):787-97. Review.

PMID:
15212619
29.

Brusatol-induced HL-60 cell differentiation involves NF-kappaB activation.

Cuendet M, Gills JJ, Pezzuto JM.

Cancer Lett. 2004 Mar 31;206(1):43-50.

PMID:
15019158
30.

Targeting aberrant signal transduction pathways in lung cancer.

Gills JJ, Granville CA, Dennis PA.

Cancer Biol Ther. 2004 Feb;3(2):147-55. Epub 2004 Feb 1. Review.

PMID:
14764993
31.

Sesquiterpenoids from Tithonia diversifolia with potential cancer chemopreventive activity.

Gu JQ, Gills JJ, Park EJ, Mata-Greenwood E, Hawthorne ME, Axelrod F, Chavez PI, Fong HH, Mehta RG, Pezzuto JM, Kinghorn AD.

J Nat Prod. 2002 Apr;65(4):532-6.

PMID:
11975495
32.

Activity-guided isolation of constituents of Cerbera manghas with antiproliferative and antiestrogenic activities.

Chang LC, Gills JJ, Bhat KP, Luyengi L, Farnsworth NR, Pezzuto JM, Kinghorn AD.

Bioorg Med Chem Lett. 2000 Nov 6;10(21):2431-4.

PMID:
11078194

Supplemental Content

Loading ...
Support Center